This is a preclinical data publication with no direct financial or regulatory catalyst. Monitor for next steps toward IND filing or human trials, which would be the next meaningful milestone for SKNY-1.
Price Chart
Executive Summary
MIRA Pharmaceuticals announced the publication of a peer-reviewed manuscript on its preclinical drug candidate SKNY-1 in the International Journal of Molecular Sciences. The study, conducted in zebrafish models, showed dose-dependent weight loss, lipid normalization, and reduced nicotine-seeking behaviors. SKNY-1 remains in preclinical development with no FDA approval or human safety/efficacy data established.
Key Facts
- Peer-reviewed manuscript on SKNY-1 published in International Journal of Molecular Sciences
- Preclinical zebrafish study showed ~30% weight reduction from baseline in high-dose group after 6 days
- SKNY-1 demonstrated CB1 pathway engagement, CB2 partial agonism, and selective MAO-B inhibition
- Additional findings: normalized cholesterol/LDL, increased HDL, reduced hepatic triglycerides, attenuated compulsive feeding and nicotine-seeking behaviors
- SKNY-1 is not FDA-approved for any indication; safety and efficacy not established in humans
Financial Impact
No financial figures reported in the filing
Risk Factors
- Preclinical results may not translate to human clinical trials
- SKNY-1 has not been approved by the FDA for any indication
- No timeline provided for clinical development or regulatory submission
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-022608 |
| Document: 0001493152-26-022608-index-headers.html | 0001493152-26-022608 |
| Document: 0001493152-26-022608-index.html | 0001493152-26-022608 |
| Document: 0001493152-26-022608.txt | 0001493152-26-022608 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | 8-K | $0.6290 $0.6195 | ▼ −1.51% | ▼ −0.99% | $0.5588 (−11.16%) |
Oct 22, 2026 5d ago | Press Release | $0.6289 $0.6195 | ▼ −1.49% | ▼ −0.97% | $0.5588 (−11.15%) |
Sep 17, 2026 5w ago | 8-K | $0.7593 $0.8323 | ▲ +9.61% | ▲ +9.73% | $0.5588 (−26.41%) |
Sep 17, 2026 5w ago | Press Release | $0.7593 $0.8323 | ▲ +9.61% | ▲ +9.73% | $0.5588 (−26.41%) |
Sep 1, 2026 8w ago | 8-K | $0.8600 $0.8495 | ▼ −1.22% | ▼ −1.66% | $0.5588 (−35.02%) |
Aug 6, 2026 11w ago | 8-K | $0.6782 $0.7400 | ▲ +9.11% | ▲ +8.50% | $0.5588 (−17.61%) |
Jul 10, 2026 15w ago | 8-K | $0.9245 $0.9097 | ▼ −1.60% | ▼ −0.84% | $0.5588 (−39.56%) |
Jul 6, 2026 16w ago | 8-K | $0.9549 $0.9478 | ▼ −0.74% | ▼ −0.27% | $0.5588 (−41.48%) |
Jun 17, 2026 18w ago | 8-K | $0.9782 $0.9524 | ▼ −2.64% | ▼ −3.42% | $0.5588 (−42.87%) |
Jun 8, 2026 20w ago | 8-K | $0.9767 $0.9802 | ▲ +0.36% | ▲ +1.93% | $0.5588 (−42.79%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers